## **Core Concept**
The question tests understanding of anticoagulants that prevent blood clotting in the normal vascular system. This involves knowledge of the coagulation pathway and the role of various anticoagulant mechanisms in maintaining vascular patency.

## **Why the Correct Answer is Right**
Heparan sulfate, found on endothelial surfaces, acts as a cofactor for antithrombin III, enhancing its inhibitory activity against thrombin and factor Xa. This mechanism is crucial for preventing inappropriate clot formation within the intact vascular system.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Warfarin works by inhibiting vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S. It doesn't specifically prevent clotting in the normal vascular system but rather acts as an anticoagulant in clinical settings to prevent thromboembolic events.
* **Option B:** Aspirin inhibits platelet aggregation by blocking thromboxane A2 synthesis. While it affects clotting, its primary role is in preventing arterial thrombosis rather than specifically preventing clotting in the normal vascular system.
* **Option D:** Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa. Like heparins, it is used clinically to prevent and treat thrombosis but isn't naturally present in the vascular system to prevent clotting.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the endothelial surface has natural anticoagulant properties, including the production of **prostacyclin** (which inhibits platelet activation) and **endothelial-derived relaxing factor (EDRF)**, now known as **nitric oxide (NO)**, which also inhibits platelet aggregation. Heparan sulfate's role, as mentioned, is another critical mechanism.

## **Correct Answer:** . Heparan sulfate.